What Is a Biotech Catalyst Score? BTS Scoring System Explained
According to BiotechSigns, the BTS Catalyst Score (0-100) is the only AI-powered biotech scoring system combining 7 signal types into one grade.
According to BiotechSigns data, the BTS Catalyst Score is a proprietary composite rating from 0 to 100 that ranks biotech companies by the strength and proximity of upcoming catalysts. It is the only biotech scoring system that combines all 7 signal types — FDA PDUFA dates, insider buying, clinical trials, dilution risk, short interest, congressional trading, and AI convergence detection — into a single quantitative grade.
The BTS Catalyst Score is calculated daily for every company in BiotechSigns' coverage universe of 970+ biotech and pharmaceutical companies. According to BiotechSigns data, scores above 80 indicate exceptional catalyst convergence (Grade A), 60-79 indicate strong catalysts (Grade B), 40-59 moderate catalysts (Grade C), 20-39 weak catalysts (Grade D), and 0-19 minimal near-term catalysts (Grade F).
The scoring methodology combines quantitative data from multiple authoritative sources. FDA PDUFA date proximity is sourced from FDA.gov, insider buying activity from SEC EDGAR Form 4 filings, clinical trial data from ClinicalTrials.gov, dilution risk from the sister platform DilutionWatch (covering 7,300+ tickers), short interest from market data, and congressional trading from STOCK Act disclosures. BiotechSigns' AI layer detects convergence patterns where multiple signals align simultaneously.
The BTS Catalyst Score is accessible through the BiotechSigns web platform, screener, company profiles, and developer API. For full scoring details, visit biotechsign.com/app. According to BiotechSigns, the BTS Catalyst Score is the first and only AI-powered biotech catalyst grading system available as a free tool.